............. 54 2. STUDY OBJECTIVES AND ENDPOINTS .......................................................................56 2.1. Part 1: Dose Escalation Objectives and Endpoints .................................................56 2.2. Part 2: Dose Expansion Objectives and Endpoints .................................................57 3. STUDY DESIGN .................................................................................................................58 3.1. Study Overview .......................................................................................................58 PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 73.1.1. Criteria for Dose Escalation........................................................................59 3.1.2. Dose Expansion (Part 2) .............................................................................60 3.2. DL T Definition ................................